Where does KaliVir Immunotherapeutcs, Inc. rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), KaliVir Immunotherapeutcs, Inc. ranks #41,170 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does KaliVir Immunotherapeutcs, Inc. hold?

KaliVir Immunotherapeutcs, Inc. holds 6 US utility patents granted between 2024 and 2025, spanning 6 technology areas.

What is KaliVir Immunotherapeutcs, Inc.'s Innovation Score?

KaliVir Immunotherapeutcs, Inc. has an Innovation Score of 48.6 out of 100 (top 16% of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does KaliVir Immunotherapeutcs, Inc. focus on?

KaliVir Immunotherapeutcs, Inc.'s top technology area is C07K (Peptides) with 6 patents, ranking #1,362 of 3,615 assignees active in that subclass. Grants appear in 6 CPC subclasses total.

Is KaliVir Immunotherapeutcs, Inc.'s patent grant rate increasing or decreasing?

Insufficient historical data is available to calculate a velocity trend for KaliVir Immunotherapeutcs, Inc..

What does claim depth mean for KaliVir Immunotherapeutcs, Inc.'s patents?

KaliVir Immunotherapeutcs, Inc.'s patents average 22.0 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the KaliVir Immunotherapeutcs, Inc. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView US Corporation

KaliVir Immunotherapeutcs, Inc.

USPTO PatentsView assignee record - 6 granted patents across 6 technology areas, recorded in grant years 2024–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: C07K (Peptides).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Kalivir ranks #41,170 of 49,997 tracked US assignees by granted-patent volume, with 6 patents across 6 technology areas.

#41,170
of 49,997 US assignees by volume: Top 16%
by Innovation Score (48.6/100): 22.0
avg claims per patent

USPTO PatentsView assignee plate

Corpus R41170 · US Corporation #41,170 · 6 grants

GRANTS-MICRO · LOWER-Q · PHOTO-FINISH · CPC-NARROW · INNOV-PAR · CLAIMS-DENSE · TYPE-USCORP · SPAN-YRS · BOOK-RICH

GRANTS-MICRO 6 grants
LOWER-Q #41,170/49,997
PHOTO-FINISH Kabbage
CPC-NARROW C07K · 6 areas
INNOV-PAR 48.6/100
CLAIMS-DENSE 22.0 claims/avg
TYPE-USCORP US Corporation
SPAN-YRS 2024–2025 · 2y
BOOK-RICH 9/10 fields

Nearest grant-volume peer: Kabbage, Inc. (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Kalivir’s 48.6 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 6.7 pts (14%) Velocity 20.0 pts (41%) Breadth 8.7 pts (18%) Claim depth 13.2 pts (27%)

Qualcomm Incorporated · highest

85
KaliVir Immunotherap… · this assignee

49
3D Lighting… · lowest

7

What this shows Kalivir's Innovation Score is 48.6/100 (top 16% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Kalivir?

Each dot is one of Kalivir’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Kalivir’s own 22.0 claims/patent is ABOVE the 11.2 median for these volume peers. More thorough claims than most filers at this scale, not just more of them.

Kalivir vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Kalivir's grants concentrate

KaliVir Immunotherapeutcs, Inc. is a focused PatentsView assignee: 6 CPC subclasses with 100% of grants classified under C07K (Peptides). By volume, Kalivir sits between Kyocera Technologies OY and Kangpu Biopharmaceuticals, Ltd..

Kalivir's three-year grant acceleration

KaliVir Immunotherapeutcs, Inc. shows 3 grants in 2022–2024 against only 0 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Kyocera OY

6
Kyowa Chemical In…

6
Kyowa Leather Clo…

6
Kabbage

6
Kalibrate

6
Kanagawa Prefectu…

6
Kang Na Hsiung En…

6
Kangpu Biopharmac…

6
Kalivir Immunothe… ◀

6

What this shows KaliVir holds 6 patents at rank #41,224, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near KaliVir

By rank, the assignees closest to #41,224 in granted patent volume.

Leaders in C07K (Peptides)

Other assignees with the most granted patents in KaliVir's primary technology class.

Kalivir's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

49 Top 16% higher than 84% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2024–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2024–2019 baseline. Full figures in the table below.

View data table

KaliVir Immunotherapeutcs, Inc. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2024	3	50.0%
2025partial year	3	50.0%

Which technologies does KaliVir Immunotherapeutcs, Inc. patent most?

C07K - Peptides 6

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 6

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 6

C12N - Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media 6

Y02A - Technologies FOR Adaptation TO Climate Change 6

C12Y - Enzymes 3

Top 6 of 6 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

KaliVir Immunotherapeutcs, Inc.'s patent record in context - here's where to go next.

KaliVir Immunotherapeutcs, Inc.'s lead technology class is C07K (Peptides), 100% of its portfolio - see every assignee active in that class. Explore C07K
Ranked #41,170 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare KaliVir Immunotherapeutcs, Inc. against Kyocera Technologies OY, an assignee filing at a similar volume. Compare portfolios
Innovation Score of 48.6/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent , US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.